|
1
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chetty R and McCarthy AJ: Neoadjuvant
chemoradiation and rectal cancer. J Clin Pathol. 72:97–101. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Häfner MF and Debus J: Radiotherapy for
colorectal cancer: Current standards and future perspectives. Visc
Med. 32:172–177. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sauer R, Becker H, Hohenberger W, Rödel C,
Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF,
et al German Rectal Cancer Study Group, : Preoperative versus
postoperative chemoradiotherapy for rectal cancer. N Engl J Med.
351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aschele C, Cionini L, Lonardi S, Pinto C,
Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti
P, et al: Primary tumor response to preoperative chemoradiation
with or without oxaliplatin in locally advanced rectal cancer:
Pathologic results of the STAR-01 randomized phase III trial. J
Clin Oncol. 29:2773–2780. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rödel C, Liersch T, Becker H, Fietkau R,
Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M,
Raab HR, et al German Rectal Cancer Study Group, : Preoperative
chemoradiotherapy and postoperative chemotherapy with fluorouracil
and oxaliplatin versus fluorouracil alone in locally advanced
rectal cancer: Initial results of the German CAO/ARO/AIO-04
randomised phase 3 trial. Lancet Oncol. 13:679–687. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cho E, Park IJ, Yeom SS, Hong SM, Lee JB,
Kim YW, Kim MJ, Lim HM, Lim SB, Yu CS, et al: A Multigene model for
predicting tumor responsiveness after preoperative
chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys.
105:834–842. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoon SM, Kim DY, Kim TH, Jung KH, Chang
HJ, Koom WS, Lim SB, Choi HS, Jeong SY and Park JG: Clinical
parameters predicting pathologic tumor response after preoperative
chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys.
69:1167–1172. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park JS, Huh JW, Park YA, Cho YB, Yun SH,
Kim HC, Lee WY and Chun HK: A circumferential resection margin of 1
mm is a negative prognostic factor in rectal cancer patients with
and without neoadjuvant chemoradiotherapy. Dis Colon Rectum.
57:933–940. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wallin U, Rothenberger D, Lowry A, Luepker
R and Mellgren A: CEA - a predictor for pathologic complete
response after neoadjuvant therapy for rectal cancer. Dis Colon
Rectum. 56:859–868. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bonner WM, Redon CE, Dickey JS, Nakamura
AJ, Sedelnikova OA, Solier S and Pommier Y: GammaH2AX and cancer.
Nat Rev Cancer. 8:957–967. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oka K, Tanaka T, Enoki T, Yoshimura K,
Ohshima M, Kubo M, Murakami T, Gondou T, Minami Y, Takemoto Y, et
al: DNA damage signaling is activated during cancer progression in
human colorectal carcinoma. Cancer Biol Ther. 9:246–252. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Klokov D, MacPhail SM, Banáth JP, Byrne JP
and Olive PL: Phosphorylated histone H2AX in relation to cell
survival in tumor cells and xenografts exposed to single and
fractionated doses of X-rays. Radiother Oncol. 80:223–229. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee YC, Yin TC, Chen YT, Chai CY, Wang JY,
Liu MC, Lin YC and Kan JY: High expression of phospho-H2AX predicts
a poor prognosis in colorectal cancer. Anticancer Res.
35:2447–2453. 2015.PubMed/NCBI
|
|
15
|
Cancer Genome Atlas Network, .
Comprehensive molecular characterization of human colon and rectal
cancer. Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gaedcke J, Grade M, Jung K, Camps J, Jo P,
Emons G, Gehoff A, Sax U, Schirmer M, Becker H, et al: Mutated KRAS
results in overexpression of DUSP4, a MAP-kinase phosphatase, and
SMYD3, a histone methyltransferase, in rectal carcinomas. Genes
Chromosomes Cancer. 49:1024–1034. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hong Y, Downey T, Eu KW, Koh PK and Cheah
PY: A ‘metastasis-prone’ signature for early-stage mismatch-repair
proficient sporadic colorectal cancer patients and its implications
for possible therapeutics. Clin Exp Metastasis. 27:83–90. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kaiser S, Park YK, Franklin JL, Halberg
RB, Yu M, Jessen WJ, Freudenberg J, Chen X, Haigis K, Jegga AG, et
al: Transcriptional recapitulation and subversion of embryonic
colon development by mouse colon tumor models and human colon
cancer. Genome Biol. 8:R1312007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Skrzypczak M, Goryca K, Rubel T, Paziewska
A, Mikula M, Jarosz D, Pachlewski J, Oledzki J and Ostrowski J:
Modeling oncogenic signaling in colon tumors by multidirectional
analyses of microarray data directed for maximization of analytical
reliability. PLoS One. 5:e130912010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ki DH, Jeung HC, Park CH, Kang SH, Lee GY,
Lee WS, Kim NK, Chung HC and Rha SY: Whole genome analysis for
liver metastasis gene signatures in colorectal cancer. Int J
Cancer. 121:2005–2012. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jorissen RN, Lipton L, Gibbs P, Chapman M,
Desai J, Jones IT, Yeatman TJ, East P, Tomlinson IP, Verspaget HW,
et al: DNA copy-number alterations underlie gene expression
differences between microsatellite stable and unstable colorectal
cancers. Clin Cancer Res. 14:8061–8069. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Watanabe T, Kobunai T, Toda E, Yamamoto Y,
Kanazawa T, Kazama Y, Tanaka J, Tanaka T, Konishi T, Okayama Y, et
al: Distal colorectal cancers with microsatellite instability (MSI)
display distinct gene expression profiles that are different from
proximal MSI cancers. Cancer Res. 66:9804–9808. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen TR, Drabkowski D, Hay RJ, Macy M and
Peterson W Jr: WiDr is a derivative of another colon adenocarcinoma
cell line, HT-29. Cancer Genet Cytogenet. 27:125–134. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Watanabe T, Itabashi M, Shimada Y, Tanaka
S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et
al Japanese Society for Cancer of the Colon and Rectum, : Japanese
Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010
for the treatment of colorectal cancer. Int J Clin Oncol. 17:1–29.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Japanese Society for Cancer of the Colon
and Rectum, . Japanese Classification of Colorectal, Appendiceal,
and Anal Carcinoma: The 3d English Edition (Secondary Publication).
J Anus Rectum Colon. 3:175–195. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kawaguchi N, Tashiro K, Taniguchi K, Kawai
M, Tanaka K, Okuda J, Hayashi M and Uchiyama K: Nogo-B
(Reticulon-4B) functions as a negative regulator of the apoptotic
pathway through the interaction with c-FLIP in colorectal cancer
cells. Biochim Biophys Acta Mol Basis Dis. 1864:2600–2609. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsuo K, Taniguchi K, Hamamoto H, Ito Y,
Futaki S, Inomata Y, Shima T, Asakuma M, Lee SW, Tanaka K, et al:
Delta-like 3 localizes to neuroendocrine cells and plays a pivotal
role in gastrointestinal neuroendocrine malignancy. Cancer Sci.
110:3122–3131. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Taniguchi K, Wada SI, Ito Y, Hayashi J,
Inomata Y, Lee SW, Tanaka T, Komura K, Akao Y, Urata H, et al:
α-Aminoisobutyric acid-containing amphipathic helical
peptide-cyclic RGD conjugation as a potential drug delivery system
for MicroRNA replacement therapy in vitro. Mol Pharm. 16:4542–4550.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Djuzenova CS, Elsner I, Katzer A,
Worschech E, Distel LV, Flentje M and Polat B: Radiosensitivity in
breast cancer assessed by the histone gamma-H2AX and 53BP1 foci.
Radiat Oncol. 8:982013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fernández MI, Gong Y, Ye Y, Lin J, Chang
DW, Kamat AM and Wu X: γ-H2AX level in peripheral blood lymphocytes
as a risk predictor for bladder cancer. Carcinogenesis.
34:2543–2547. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mei L, Hu Q, Peng J, Ruan J, Zou J, Huang
Q, Liu S and Wang H: Phospho-histone H2AX is a diagnostic and
prognostic marker for epithelial ovarian cancer. Int J Clin Exp
Pathol. 8:5597–5602. 2015.PubMed/NCBI
|
|
32
|
Le DT, Durham JN, Smith KN, Wang H,
Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et
al: Mismatch repair deficiency predicts response of solid tumors to
PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wakasugi M, Sasaki T, Matsumoto M, Nagaoka
M, Inoue K, Inobe M, Horibata K, Tanaka K and Matsunaga T:
Nucleotide excision repair-dependent DNA double-strand break
formation and ATM signaling activation in mammalian quiescent
cells. J Biol Chem. 289:28730–28737. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim NK, Park JK, Lee KY, Yang WI, Yun SH,
Sung J and Min JS: p53, BCL-2, and Ki-67 expression according to
tumor response after concurrent chemoradiotherapy for advanced
rectal cancer. Ann Surg Oncol. 8:418–424. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chang HJ, Jung KH, Kim DY, Jeong SY, Choi
HS, Kim YH, Sohn DK, Yoo BC, Lim SB and Kim DH: Bax, a predictive
marker for therapeutic response to preoperative chemoradiotherapy
in patients with rectal carcinoma. Hum Pathol. 36:364–371. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kobayashi H, Hashiguchi Y, Ueno H, Shinto
E, Kajiwara Y and Mochizuki H: Absence of cyclooxygenase-2 protein
expression is a predictor of tumor regression in rectal cancer
treated with preoperative short-term chemoradiotherapy. Dis Colon
Rectum. 50:1354–1362. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shinto E, Hashiguchi Y, Ueno H, Kobayashi
H, Ishiguro M, Mochizuki H, Yamamoto J and Hase K: Pretreatment
CD133 and cyclooxygenase-2 expression as the predictive markers of
the pathological effect of chemoradiotherapy in rectal cancer
patients. Dis Colon Rectum. 54:1098–1106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kang SJ, Lee YJ, Kang SG, Cho S, Yoon W,
Lim JH, Min SH, Lee TH and Kim BM: Caspase-4 is essential for
saikosaponin a-induced apoptosis acting upstream of caspase-2 and
γ-H2AX in colon cancer cells. Oncotarget. 8:100433–100448. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Redon CE, Nakamura AJ, Zhang YW, Ji JJ,
Bonner WM, Kinders RJ, Parchment RE, Doroshow JH and Pommier Y:
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic
biomarkers. Clin Cancer Res. 16:4532–4542. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang H, Luo J, Liu Z, Zhou R and Luo H:
MicroRNA-138 regulates DNA damage response in small cell lung
cancer cells by directly targeting H2AX. Cancer Invest. 33:126–136.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xu C, Zhang L, Duan L and Lu C:
MicroRNA-3196 is inhibited by H2AX phosphorylation and attenuates
lung cancer cell apoptosis by downregulating PUMA. Oncotarget.
7:77764–77776. 2016. View Article : Google Scholar : PubMed/NCBI
|
